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rug-Eluting Stent Fracture
romise and Performance*
ndrew J. Carter, DO
ucson, Arizona
All promise outruns performance.
—Ralph Waldo Emerson (1)
he saga of drug-eluting stents (DES) continues from their
yperbolic introduction into clinical practice in 2003
hrough a period of scrupulous clinical safety introspection,
merging as the principal device therapy for percutaneous
oronary intervention with renewed enthusiasm in today’s
ra of prolonged oral dual antiplatelet therapy. Clinicians,
esearchers, industry, and regulatory agencies have gained
isdom from the many lessons taught in the global intro-
uction of DES into clinical practice. As clinicians and
cientists, we benefit from an organized cognitive approach
o solve clinical problems or test new hypothesis. To the risk
f oversimplification, one can systematically summarize our
xperience with DES in clinical practice as a series of
essons: 1) the early signals of potential unanticipated safety
ssues of hypersensitivity reactions and late thrombosis from
See page 1924
linical case reports and post-market surveillance registries
2,3); 2) post-market observational studies from indepen-
ent researchers elicited concern regarding the long-term
afety and efficacy of DES in comparison with bare-metal
tents (BMS) (4); 3) clinical and pathologic studies identify
elayed healing as the likely mechanism for late and very
ate DES thrombosis (5); and 4) observational studies
ndicate a lower probability of late stent thrombosis with
ptimal stenting techniques, careful case selection, and
rolonged dual oral antiplatelet therapy with aspirin and
lopidogrel (6,7). Thus, the early signals after introduction
f DES into clinical practice generated safety concerns
upported by long-term observational data that defined the
roblem of late thrombosis, which necessitated refinements
n clinical practice to improve patient outcomes.
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Tucson Medical Center, Tucson, Arizona. Dr. Carter has served as ar
onsultant for XTENT, Inc. and has equity in XTENT, Inc., Ostial Solutions, and
etagon, Inc.In this issue of the Journal, Nakazawa et al. (8) provide
nique pathologic insights into the frequency, anatomic,
orphologic, and clinical histologic events associated with
tent strut fracture, yet another lesson learned with DES.
he assumption that commercially available BMS were
uitability designed to serve as a vehicle for drug delivery is
ubious, given recent clinical reports of adverse cardiac
vents associated with DES strut fracture and the patho-
ogic data first reported in the Journal.
The aim of the study by Nakazawa et al. (8) was to assess
he incidence of stent fracture at autopsy using high-
ontrast film-based radiography and to investigate the
mpact of stent fracture on the pathologic findings and
istologic clinical outcomes. This pathological study in-
luded 170 consecutive lesions derived from a single-center
ost-mortem DES registry suitable for high-contrast film-
ased stent radiography and light microscopy to define the
ncidence of thrombosis and restenosis for stents with and
ithout strut fracture. The authors developed a radiographic
lassification for strut fracture based on the number of
ractured struts and associated material defects of the stent.
trut fracture was classified as grade I (single-strut fracture),
rade II (2 fractured struts), grade III (2 fractured struts
ith deformation), grade IV (strut fractures with transection
ithout gap), and grade V (strut fractures with gap within
he stent body).
In this pathologic study, the authors reported a higher
requency of DES strut fracture than previously described by
linical observational studies that utilized angiographic
ethods to detect strut fracture. Case studies and single-
enter clinical observational studies report an approximate
% to 5% incidence of DES strut fracture (9). In the
athologic study by Nakazawa et al. (8), DES strut fracture
as detected in 51 of 177 (29%) lesions examined in this
ost-mortem cohort. The differences in the observed fre-
uency of DES strut fracture in the clinical and pathologic
tudies likely reflects the inferior resolution of imaging
echniques applied in clinical research compared with the
ethods for pathologic analysis of stents, although the
ossibility of selection bias indeed may contribute to the higher
requency of DES strut fracture reported in the present
athologic study. The systematic pathologic analysis applied
n the report by Nakazawa et al. (8), however, yields critical
ovel insight into the mechanisms and potential clinical
vents associated with stent strut fracture dependent on the
ode of mechanical failure of the prosthesis.
The high-resolution post-mortem radiography utilized in
his pathologic study enables more precise identification and
ocalization of strut fracture, as well as the ability to assess
verall mechanical integrity of the prosthesis. The majority
f DES strut fractures were minor and not associated with
echanical failure as manifested by an acquired intrastent
ap or deformation of the structure (grades I, II, and IV).
trut fractures with an acquired gap or stent fracture were










































































































1933JACC Vol. 54, No. 21, 2009 Carter
November 17, 2009:1932–4 Drug-Eluting Stent Fractureonsistent with the clinical angiographic data reported by
thers (9). The presence of stent fracture, grade V or severe,
as associated with a histologic event, such as thrombosis or
estenosis, in 71% of cases. The pathologic data by Naka-
awa et al. (8) substantiate clinical reports of a higher
requency of adverse events with stent fracture or mechan-
cal failure of DES stent platform. Importantly, the fre-
uency and mode of failure may differ for the first-
eneration Food and Drug Administration-approved DES
nd the nature of the implant technique.
The axial location of stent strut fracture varied by stent
ype; the majority of the fractures in the Cypher (Cordis,
iami Lakes, Florida) stents were located in flexible
-shaped, undulating longitudinal intersinusoidal-ring
onnectors, whereas in Taxus Express (Boston Scientific,
atick, Massachusetts) stents, fractures were observed in
he straight longitudinal intercrown linker or the modular
ing portion. Furthermore, in single stented lesions, the
ajority of stent fractures were localized in the mid portion
f the stent body, except for stents 25-mm length, where
he fracture sites were slightly shifted toward the proximal
argin. In cases with overlapped stents, most fractures were
bserved within 5-mm of the overlap zone, with similar
requency in proximal and distal stents. Lesions with strut
racture had a 4-fold longer duration of stent implant
fracture: mean 172 days vs. nonfracture: mean 40 days),
ore often observed with Cypher stents, had 50% longer
tent length, greater number of stents per lesion, and more
ommonly observed with overlapped stents in comparison
o DES without strut fracture. DES strut fractures tended
o be more commonly observed in the right coronary artery
nd in aortocoronary saphenous vein bypass grafts. Longer
tent length, use of Cypher stent, and longer duration of
mplant were identified as independent risk factors of stent
ractures by a logistic regression analysis. Interestingly, the
egree of vessel calcification did not impact on the fre-
uency of stent strut fracture.
In the pre-DES era, strut fracture or stent deformation
as considered as rare, uncommon events usually observed
n the application of stents in anatomic locations associated
ith unique implant techniques (i.e., bifurcation) or when
xposed to traumatic extravascular forces (i.e., carotid or
opliteal artery). The emergence of stent strut fracture in
he era of DES warrants further investigation to determine
hy apparently mechanically robust balloon expandable
tents have a notably higher rate of material fatigue/failure
hen utilized as a vehicle for drug delivery in comparison to
hen serving only as a scaffold in the coronary artery.
re-clinical studies suggest that selected DES may be more
rone to fracture than a BMS in a porcine coronary overlap
odel (10).
Metallic materials may fail due to the extension of
rocessing defects such as pores, inclusions, or cracks.
nder constant or cyclic loading, the defects may extend
lowly until a critical size is reached, when unstable exten-
ion occurs. The subcritical extension of the defects under sonstant loading is called static fatigue, subcritical extension
nder cyclic loading is called cyclic fatigue. It seems unlikely
hat the observed differences in mechanical stent failure in
he BMS versus the DES era relates to changes in material
pecifications of uniform tubes, laser manufacturing, or
leaning of residual debris to produce the BMS. These
evices were tested prior to regulatory approval with expo-
ure to similar in vitro loading conditions and repeated
yclic stress with presumably similar modes and frequency of
ailure. The methods utilized to prepare the stent surface for
oating, polymer coating materials, and drug may affect the
urability of the prosthesis through various in vivo pathways
uch as corrosion that may a provide plausible but an
nlikely mechanism for DES strut fracture given the in vivo
xposure ranging from 0.1 to nearly 2 years reported in the
resent study. Interestingly, platinum and cobalt chromium,
he alloys used in later generation DES, are less susceptible
o corrosion than 316L stainless steel (11).
It is important to note that computational methods such
s finite element analysis utilized in the design of stents
implify conditions to static or dynamic loads without
ccounting for variance in biologic events such as neointimal
ncorporation of the stent into the vessel wall. The localized
tress imparted on nonapposed struts or areas of incomplete
r absent neointimal coverage likely differs from stent struts
pposed to the vessel wall embedded in 100 to 200 m of
eointima.
Future design of DES stent platforms and preclinical
atigue testing should be adapted to account for the biolog-
cal conditions endured during the life of the implanted
rosthesis. The frequency of stent strut fracture for later
eneration DES with thin-strut cobalt chromium alloys is
nknown but will likely differ from the thick-strut stainless
teel first-generation DES. Clinical trials should incorporate
pecific end points to ascertain the frequency and pattern of
tent strut fracture for novel DES. The application of
4-slice cardiac computed tomography angiography appears
o be a promising technique that could be utilized to further
valuate the structural integrity of stents in patients with
bserved clinical events or suspected strut fracture (12).
Despite the limitations of previous clinical reports and
he present pathologic study, the frequency of DES strut
racture is higher than anticipated, given our experience
ith BMS. DES strut fracture is more often an incidental
linical finding isolated to a single strut. In more complex
oronary disease, DES strut fracture can be severe, resulting
n transection of the stent and creating a gap or segment of
echanical failure associated with a high rate of adverse
linical events such as late thrombosis or restenosis. The
ptimal clinical management of patients with isolated or
ncidental DES strut fracture is unknown. Clinical obser-
ation and extension of dual antiplatelet therapy beyond 1
ear should be considered in each case. In patients with
tent fracture, extended dual antiplatelet therapy should
hen be strongly considered together with percutaneous or
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Drug-Eluting Stent Fracture November 17, 2009:1932–4xtent of myocardial ischemia on functional testing, and
ssociated anatomic severity of coronary obstruction. The
rocedural success rates and long-term clinical outcomes for
ercutaneous coronary intervention (POBA [”plain old
alloon angioplasty”], BMS, or DES) in patients with DES
racture have not been established.
The latest lesson learned with DES is the false assump-
ion or “promise” that all bare-metal, balloon-expandable
tent designs are suitable for drug delivery. Others have
aught the importance of strut uniformity and apposition to
he vessel wall to achieve homogeneous drug delivery (13).
he development of stent designs to optimize drug delivery
hile maintaining structural integrity is critical in order to
dvance the application of DES in patients with more
omplex coronary artery disease.
eprint requests and correspondence: Dr. Andrew J. Carter,
ucson Medical Center, 6206 East Pima Street, Suite 4, Tucson,
rizona 85712-7001. E-mail: acarter@heartaz.com.
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